Please login to the form below

Not currently logged in
Email:
Password:

Biotech and vaccines focus for sanofi-aventis

French drugs maker sanofi-aventis has announced that it plans to shift its emphasis to biotechnology and vaccine production

French drugs maker sanofi-aventis (S-A) has announced that by 2014 it plans to shift its emphasis to biotechnology and vaccine production in France, and away from the chemical production of drugs.

The company is presenting employees with its plans to invest €150m in the transfer, which will entail training programmes and the creation of the group's third largest European vaccine production site.

The company said the move reflects its shift in business from producing drugs through synthetic chemistry following patent expirations of several key drugs.

The new activities will create jobs locally, the company said.

31st March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics